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STRUCTURED ABSTRACT  
Aims: Improved treatments for prostate cancer are critically needed in order to 
overcome metastasis and lethal recurrence. Intravenously administered gene therapy 
would be an attractive anti-cancer treatment strategy, however the lack of suitable 
carrier systems able to selectively deliver therapeutic genes to tumors has so far 
limited this investigation. Given that transferrin receptors are overexpressed on 
prostate cancer cells, the purpose of this study is to determine whether transferrin-
bearing dendriplex encoding TNF±, TRAIL and IL-12 would suppress the growth of 
prostate cancer cell lines in vitro and in vivo.  
Materials & Methods: Transferrin-bearing dendriplexes encoding TNF±, TRAIL and 
IL-12 were intravenously administered to mice bearing subcutaneous PC-3 and 
DU145 tumors. 
Results: The administration of the DAB-Tf dendriplex encoding TNF± resulted in 
tumor suppression for 60% of PC-3 and 50% of DU145 prostate tumors. 
Conclusions: These dendriplexes hold great potential as a novel approach for 
prostate cancer therapy. 
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INTRODUCTION 
Prostate cancer is one of the most commonly diagnosed malignancies in men and 
remains the second leading cause of cancer-related deaths in the United States and 
the European Union. Although radiation therapy, chemotherapy, radical 
prostatectomy and cryoablation can be efficacious therapies for localized tumors, 
there is still no effective treatment modality for patients with recurrent or metastatic 
disease [1]. New treatment approaches are therefore critically needed for these 
patients.  
Among novel experimental strategies, gene therapy holds great promise for the 
treatment of prostate cancer. The identification of the genetic mutations involved in 
this disease has led to the development of a wide panel of highly diverse, rapidly 
evolving gene therapy approaches, such as corrective gene therapy, suicide gene 
therapy, apoptosis-inducing gene therapy and immunomodulation therapy [1]. These 
approaches have already shown promise for in situ use. For example, in a phase I/II 
clinical trial, the in situ delivery of an adenoviral vector delivery of the Herpes Simplex 
Virus thymidine kinase gene followed by the pro-drug ganciclovir resulted in 
apoptosis of prostate cancer cells and immune cell activation [2, 3].  
However, the use of gene therapy is currently limited by the lack of delivery systems 
able to selectively deliver the therapeutic genes to the tumors by intravenous 
administration, without secondary effects to normal tissues.  In order to overcome 
this problem, we recently demonstrated that the conjugation of transferrin (whose 
receptors are abundantly expressed on cancer cells) to generation 3- diaminobutyric 
polypropylenimine (DAB) dendrimer led to gene expression principally in the tumors 
following intravenous administration [4]. As a result, the intravenous administration of 
DAB-Tf dendrimer complexed to the Tumor Necrosis Factor (TNF±) expression 
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plasmid led to tumor suppression for 90% of the A431 epidermoid carcinoma tumors, 
with long-term survival of the mice. 
Building on these promising results, we have focused on investigating if this delivery 
system carrying plasmids encoding for TNF±, tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) or interleukin-12 (IL-12), could lead to therapeutic 
effects on prostate cancer following intravenous administration.  
TRAIL, a member of the TNF family of cytokines, is particularly promising in the 
development of anti-cancer therapeutics, as it preferentially induces apoptosis of 
cancer cells whilst sparing normal cells [5].  Its binding to death receptors DR4 and 
DR5 leads to recruitment of Fas-associated death domain, resulting in tumor cell 
death via caspase-dependent apoptotic pathways [5]. As it has a short biological half-
life and is rapidly cleared from the circulation after intravenous administration [6], new 
delivery strategies are particularly needed to improve its therapeutic potency.  
Another cytokine, IL-12, has been shown to be efficacious in the induction of potent 
antitumor immunity [7]. IL-12 has multiple effects on B cells, T cells and natural killer 
cells and is also a major regulator of Th1 cell differentiation.  In animal melanoma 
models, the administration of IL-12 plasmid resulted in tumor growth inhibition in 
addition to regression of established tumors [8]. However, the intravenous use of IL-
12 is hampered by its potential side effects [9], thus emphasizing the need of tumor-
specific delivery.   
The objectives of this study were therefore to investigate if transferrin-bearing DAB 
dendrimer complexed with TNF±, TRAIL or IL-12 expression plasmids had a 
therapeutic effect on prostate cancer cells in vitro and in vivo after intravenous 
administration. 
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MATERIALS & METHODS 
Cell lines and reagents  
Generation 3- diaminobutyric polypropylenimine dendrimer (DAB), iron-saturated 
human holo-transferrin, dimethylsuberimidate and the other reagents were from 
Sigma Aldrich (Poole, UK). The expression plasmids encoding ² -galactosidase 
(pCMVsport ² -galactosidase) and TNF± (pORF9-mTNF±) were purchased 
respectively from Invitrogen (Paisley, UK) and InvivoGen (San Diego, CA), while the 
expression plasmids encoding TRAIL (pORF9-mTRAIL) and IL-12 (pORF-mIL12) 
came from Source BioScience (Nottingham, UK). These plasmids were purified using 
an Endotoxin-free Giga Plasmid Kit (Qiagen, Hilden, Germany). Label IT® Cy3 
Nucleic Acid Labeling kit was purchased from Cambridge Biosciences (Cambridge, 
UK). Passive lysis buffer came from Promega (Southampton, UK). Androgen-
irresponsive DU145 and androgen-responsive LNCaP human prostate carcinomas 
were obtained from the European Collection of Cell Cultures (Salisbury, UK). Firefly 
D-luciferin and Bioware® androgen-irresponsive PC-3M-luc-C6 human prostate 
adenocarcinoma that expresses the firefly luciferase were from Caliper Life Sciences 
(Hopkinton, MA). Tissue culture media were obtained from Invitrogen (Paisley, UK). 
 
Preparation of transferrin-bearing polypropylenimine dendrimer 
Generation 3- diaminobutyric polypropylenimine dendrimer (DAB, 24 mg) was 
conjugated to transferrin (Tf, 6 mg) by cross-linking  with dimethylsuberimidate 
(DMSI, 12 mg) in triethanolamine HCl buffer (pH 7.4, 2 mL), as previously described  
[4, 10]. The conjugation reaction took place at 25oC for 2 h whilst stirring. DAB-Tf 
dendrimer was then purified by size exclusion chromatography using a Sephadex 
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G75 column, freeze-dried, before having its identity confirmed by 1H NMR 
spectroscopy, using a Jeol Oxford NMR AS 400 spectrometer [4].   
 
 In vitro studies 
Cell culture  
PC-3M-luc-C6, DU145 and LNCaP prostate cell lines overexpressing Tf receptors 
were grown in either MEM (for PC-3 and DU145 cells) or RPMI medium (for LNCaP 
cells), at 37oC in a humidified atmosphere under 5% CO2. Fetal bovine serum (10% 
(v/v), L-glutamine (1% (v/v) and penicillin-streptomycin (0.5% (v/v) were added to 
both media. In addition, RPMI medium was also supplemented with 10 mM HEPES 
(5 mL) and 1 mM sodium pyruvate (5 mL).  
 
Cellular uptake of DNA  
Plasmid DNA encoding ² -galactosidase was labeled with the fluorescent probe Cy3 
using a Label IT® Cy3 Nucleic Acid Labeling kit, as described by the manufacturer. 
PC-3, DU145 and LNCaP cells were seeded on coverslips in 6-well plates (104 cells/ 
well) and grown at 37oC for 24 h. They were then incubated with Cy3-labeled DNA 
(2.5 µg DNA / well) complexed by mixing to DAB-Tf and DAB at their optimal 
dendrimer: DNA weight ratios (leading to complete DNA condensation and highest 
transfection) respectively of 10:1 for DAB-Tf and 5:1 for DAB [10, 11]. Control slides 
were treated with naked DNA. Following 24 h treatment, the cells were then washed 
three times with PBS and fixed with methanol for 10 min. DAPI was then used to 
stain the nuclei and the cells were examined using a Leica TCS SP5 confocal 
microscope. DAPI was excited with the 405 nm laser line (bandwidth: 415-491nm), 
whereas Cy3 was excited with the 543 nm laser line (bandwidth: 550-620 nm). Cy3-
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related fluorescence intensity was then quantified in each of the confocal microscopy 
pictures by using Adobe Photoshop Elements software. Results were expressed as 
fluorescence intensity (in arbitrary units) per cell.  
 
In vitro transfection 
Transfection efficacy of the plasmid DNA encoding ² -galactosidase and carried by 
DAB-Tf dendrimer was evaluated by a ² -galactosidase transfection assay. Following 
seeding at a density of 2000 cells/ well in 96-well plates, PC-3, DU145 and LNCaP 
cells were left to grow at 37oC for 72 h. They were then incubated for a further 72 h 
with DNA (10 µg/mL), alone or complexed to DAB-Tf and DAB (dendrimer: DNA 
weight ratios of 10:1 for DAB-Tf and 5:1 for DAB). The cells were then lysed with 50 
µL/well of 1X passive lysis buffer (PLB) for 20 min, before being incubated with 50 
µL/well of assay buffer (2 mM magnesium chloride, 100 mM mercaptoethanol, 1.33 
mg/mL ¿-nitrophenol-² -galactopyranoside, 200 mM sodium phosphate buffer, pH 7.3) 
for 2 h at 37oC. The absorbance of the samples was then read at 405 nm with a plate 
reader (Thermo Lab Systems, Multiscan Ascent, UK) [4]. 
 
In vitro anti-proliferative activity 
Following seeding at a density of 2000 cells/ well in 96-well plates, PC-3, DU145 and 
LNCaP cells were left to grow at 37oC for 72 h. They were then incubated with DAB-
Tf dendriplexes encoding TNF±, TRAIL and IL-12, at final DNA concentrations of 
1.28x10-3 to 100 µg/mL. After 72 hours incubation with the treatment, anti-
proliferative activity was assessed by using a standard MTT assay [4] (three 
independent experiments with n=5 for each concentration level). The incubation of 
the treatments with the cells was maintained for 72 h, in order to allow comparison 
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with our previous cytotoxicity results, obtained with DAB-Tf dendrimer but with 
different therapeutic DNA and different cancer cells.  
 
 In vivo tumoricidal activity 
The in vivo experiments described below were approved by the local ethics 
committee and performed in accordance with the UK Home Office regulations. 
PC-3M-luc-C6 and DU145 cancer cells in exponential growth were subcutaneously 
implanted to both flanks of male immunodeficient BALB/c mice (1 x 10 6 cells per 
flank). When tumors became palpable, vascularized and reached a diameter of 5 
mm, the mice were split into groups of five  before being intravenously injected with 
the treatments, namely  Tf-bearing DAB dendrimer complexed with TNF±, TRAIL or 
IL-12 expression plasmids, the targeted dendrimer and naked DNA (50 µg of DNA) 
once daily for 10 days. The weight of the mice was measured every day to evaluate 
the toxicity of the treatments and tumor volume was determined by caliper 
measurements (volume = d3 x À/6).  
Bioluminescence imaging using an IVIS Spectrum (Caliper Life Sciences, Hopkinton, 
MA) was also used to monitor the therapeutic efficacy of the treatments. To this end, 
mice bearing subcutaneous PC-3M-luc-C6 tumors were intravenously injected with 
treatments as described above. Ten minutes before imaging, they were 
intraperitoneally injected with the luciferase substrate D-luciferin (150 mg/kg body 
weight), before being anaesthetized by isoflurane inhalation on Days 1, 3, 5, 7, 9 of 
the experiment. The light emitted from the bioluminescent tumors was detected for 2 
min using Living Image® software and displayed as a pseudo-color overlay onto a 
gray scale image of the animal. Identical illumination settings were used for acquiring 
all images [12]. 
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Statistical Analysis 
Results were expressed as means ± standard error of the mean (S.E.M). Statistical 
significance was assessed by one-way analysis of variance (ANOVA) and Bonferroni 
multiple comparison post-test (GraphPad Prism software). P values lower than 0.05 
were considered statistically different.  
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RESULTS  
Cellular uptake of DNA 
Confocal microscopy experiments confirmed that Cy3-labelled DNA was taken up by 
PC-3, DU145 and LNCaP cells (Figure 1). The fluorescently-labeled DNA was found 
to be disseminated in the cytoplasm following treatment with DAB-Tf and DAB 
dendriplexes in the three tested cell lines. However, the DNA uptake appeared to be 
much more pronounced after treatment with Tf-bearing dendriplex than with the non-
targeted dendriplex, corresponding to an increase in fluorescence intensity of 
respectively 1.5-fold in PC-3 cells, 6-fold in DU145 cells and 15-fold in LNCaP cells 
(Figure 1). DNA appeared to be more efficiently taken up by PC-3 cells when 
delivered by means of the targeted dendriplex, compared to LNCaP and DU145 
cells. However, these results need to be taken with caution, as they correspond to 
the quantification of one single representative confocal microscopy picture. No 
statistical analysis can therefore be applied to these results.  
Co-localization of DNA in the nuclei was visible in the 3 cell lines following treatment 
with Tf-bearing dendriplex, as well as in PC-3 cells following treatment with DAB 
dendriplex, but to a lesser extent. By contrast, no Cy3-derived fluorescence was 
visible in cells treated with naked DNA. The conjugation of Tf to DAB therefore 
improved the uptake of DNA by PC-3, DU145 and LNCaP prostate cancer cells.  
 
In vitro transfection  
Treatment with DAB-Tf dendriplex led to an increase in gene expression on both PC-
3 and LNCaP cells (Figure 2).  On PC-3 cells, gene expression following treatment 
with DAB-Tf dendriplex (2.69x10-3 ± 0.09x10-3 U/mL) was 1.3-fold higher than with 
unconjugated DAB dendriplex (2.08x10-3 ± 0.09x10-3 U/mL). Similarly, it was slightly 
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higher following treatment with DAB-Tf dendriplex (1.77x10-3 ± 0.11x10-3 U/mL) than 
that observed with DAB dendriplex (1.53x10-3 ± 0.05x10-3 U/mL) on LNCaP cells. 
However, there was no significant difference between gene expression following 
treatment with DAB-Tf dendriplex and DAB dendriplex on DU145 cells (1.47x10-3 ± 
0.10x10-3 U/mL and 1.29x10-3 ± 0.11x10-3 U/mL respectively). Treatment with control 
dendrimer and naked DNA only resulted in weak levels of gene expression, as 
expected.  
 
 In vitro anti-proliferative activity  
DAB-Tf complexed to TNF±, TRAIL and IL-12 expression plasmids significantly 
enhanced the in vitro anti-proliferative efficacy on the three prostate cancer cell lines 
when compared to the unconjugated dendriplex (Table 1). When complexed to TNF± 
expression plasmid, it significantly increased the in vitro therapeutic effect by 5.1-fold 
in PC-3 cells (IC50: 0.27 r 0.04 µg/mL), 1.7-fold in DU145 cells (IC50: 1.26 r 0.11 
µg/mL) and by more than 100-fold in LNCaP cells (IC50: 1.01 r 0.07 µg/mL), 
compared to the unconjugated dendriplex. It was most efficacious on PC-3 cells, 
followed by LNCaP cells and then DU145 cells. 
When complexed to TRAIL expression plasmid, DAB-Tf also increased the anti-
proliferative activity, this time by 21-fold in PC-3 cells (IC50: 0.85 r 0.03 µg/mL), 3.5-
fold in DU145 cells (IC50: 0.81 r 0.04 µg/mL) and 5.2-fold for LNCaP cells (IC50: 1.16 
r 0.24 µg/mL), compared to the unconjugated dendriplex. DAB-Tf dendriplex 
expressing TRAIL was most efficacious on DU145 cells, closely followed by PC-3 
cells and then LNCaP cells.   
Finally, DAB-Tf complexed to Il-12 expression plasmid led as well to an increased 
anti-proliferative activity in comparison with the unmodified dendriplex, by 1.7-fold for 
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PC-3 cells (IC50: 1.11 r 0.16 µg/mL), 1.5-fold for DU145 cells (IC50: 0.80 r 0.09 
µg/mL) and more than 30-fold for LNCaP cells (IC50: 3.31 r 0.25 µg/mL). It was most 
efficacious on DU145 cells, followed by PC-3 cells and then LNCaP cells, as 
observed with TRAIL-expressing DAB-Tf dendriplex.  
Overall, the most efficacious treatment observed in this in vitro study was DAB-Tf 
dendriplex expressing TNF± on PC-3 cells. By contrast, uncomplexed DAB-Tf, DAB 
and naked DNA did not exert any cytotoxicity to the cells at the tested 
concentrations, thus demonstrating that 1) DAB-Tf and DAB dendrimers were safe 
for the cells in the range of concentrations used in our experiments and 2) that a 
tumor-targeted delivery system is needed for the effective delivery, transfection and 
subsequently efficacy of the therapeutic DNA on prostate cancer cells.  
 
In vivo study 
The intravenous administration of DAB-Tf dendriplex encoding TNF± resulted in PC-
3 tumor regression within 24h (Figure 3). This effect was maintained for 4 days, 
allowing the tumors to shrink to nearly half their initial size. From Day 5, some tumors 
kept regressing while others started growing, resulting in an overall slowdown of PC-
3 tumor growth compared to the other treatments (Figure 3). From Day 15, the mice 
bearing growing tumors had to be euthanized due to their tumors reaching the 
maximum allowed size. The remaining mice, whose tumors were regressing or had 
completely disappeared, were kept until the end of the study.  
The replacement of TNF± by TRAIL expression plasmid led to a different tumor 
growth pattern following administration of DAB-Tf dendriplex. A smaller number of 
PC-3 tumors were regressing compared to that observed with TNF± gene therapy, 
resulting in an overall slowdown of PC-3 tumor growth compared to controls.  
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Following administration of DAB-Tf dendriplex encoding IL-12, PC-3 tumors slowly 
started regressing until Day 5. From that day, some of them started growing, 
resulting in an overall slowdown of PC-3 tumor growth compared to controls. Unlike 
that observed with TNF±, none of the tumors completely disappeared.  
Treatment of the DU145 tumors with DAB-Tf dendriplex encoding TNF± resulted in 
an overall slowdown of tumor growth compared to controls, although some tumors 
were regressing (Figure 4). From Day 20, only the mice bearing regressing tumors or 
no longer any tumors were still in the study.  
DAB-Tf dendriplex encoding TRAIL initially led to an overall stable response for 9 
days, followed by tumor growth.  
The administration of DAB-Tf dendriplex encoding IL-12 resulted in an initial tumor 
regression for 5 days, followed by a very slow tumor growth. By contrast, all the PC-3 
and DU145 tumors treated with DAB-Tf, naked DNA or left untreated, were growing 
throughout the experiment.  
On the last day of the experiment, 60% of PC-3 and 50% of DU145 tumors treated 
with DAB-Tf dendriplex encoding TNF± had completely disappeared, while another 
10% of DU145 tumors showed a partial response (Figures 3 and 4). As a result of 
treatment with DAB-Tf dendriplex encoding TRAIL, 10% of PC-3 tumors showed a 
complete disappearance, 20% of these tumors were regressing, while no DU145 
tumors were responsive to this treatment. Finally, treatment with DAB-Tf dendriplex 
encoding IL-12 did not lead to any tumor disappearance on both tumor types. Only 
20% PC-3 tumors showed a partial response, while another 20% remained stable. 
For DU145 cell line, 20% of the tumors also showed a partial response, while 10% 
were stable. All the tumors treated with DAB-Tf, naked DNA or left untreated were 
progressive for both tumor types. 
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The therapeutic effect resulting from treatment with DAB-Tf dendriplexes was also 
qualitatively confirmed by bioluminescence imaging on mice bearing subcutaneous 
PC-3M-luc-C6 tumors (Figure 5). Following treatment with DAB-Tf dendriplex 
encoding TNF±, luciferase expression in the tumors gradually decreased from Day 1 
to Day 11, to completely disappear at Day 11 as a result of the suppression of the 
entire tumor. Following treatment with DAB-Tf dendriplex encoding TRAIL, the 
tumors were regressing without completely disappearing at Day 11. As a result of the 
treatment with DAB-Tf dendriplex encoding IL-12, the tumors appeared to remain 
stable. All the other treatments led to an increase of luciferase expression in the 
growing tumors.  
The improved therapeutic efficacy observed with DAB-Tf dendriplexes treatment 
resulted in an extended survival of 22 days compared to untreated tumors, for both 
cell lines (Figures 3 and 4). Treatment with naked DNA only extended the survival of 
the animals by 1 or 2 days compared to untreated mice. 
No apparent sign of toxicity or significant weight loss were observed, suggesting that 
all treatments were well tolerated by the mice (Figures 3 and 4).  
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DISCUSSION 
The use of gene therapy for the treatment of recurrent prostate cancer and its 
metastasis is currently hampered by the lack of safe and efficacious gene delivery 
systems able to deliver therapeutic genes to their site of action following intravenous 
administration, without secondary effects to normal tissues. In order to remediate to 
this problem, we hypothesized that a generation 3- diaminobutyric polypropylenimine 
(DAB) dendriplex encoding TNF±, TRAIL and IL-12 and conjugated to transferrin, 
would improve the delivery of therapeutic DNA and suppress the growth of prostate 
cancer cell lines in vitro and in vivo. Transferrin receptors are abundantly expressed 
on prostate cancer cells [13] and have been successfully used for the delivery of 
liposomes to prostate tumors [14], thus making a transferrin-based tumor targeting 
strategy particularly interesting to explore on prostate cancer cells with the DAB 
dendrimer delivery system. In addition, the combination of transferrin-based active 
targeting and passive targeting due to the accumulation of dendriplexes resulting 
from the enhanced permeability and retention effect should provide a tumor-selective 
targeting to these dendriplexes.   
Furthermore, generation 3-DAB dendrimer presents the advantage of having 100% 
protonable nitrogens [15], making it particularly suitable for binding the negatively 
charged DNA by electrostatic interactions [16].  
In this study, we successfully demonstrated that the conjugation of Tf on the 
dendriplexes improved DNA uptake by the three prostate cancer cell lines studied, 
compared to control dendriplexes and naked DNA treatment. Tf receptor-mediated 
uptake of DNA and drugs has been extensively studied on numerous cancer cell 
lines [17-22], but rarely on prostate cancers. Although the difference between 
treatments was less pronounced in our study, our results were in accordance with 
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previous data obtained by Sahoo and colleagues [23], who demonstrated that the 
uptake of Tf-conjugated, paclitaxel-loaded nanoparticles was about 3-fold higher than 
that of unconjugated nanoparticles in PC-3 cells. The enhanced DNA uptake 
resulting from treatment of the cells with a transferrin-bearing delivery system could 
be explained by the level of transferrin receptor protein expression on these  prostate 
cancer cell lines. Liu previously demonstrated that transferrin receptors were 
overexpressed on PC-3, DU145 and LNCaP cells, with a higher level of expression 
on the surface of PC-3 cells [13]. 
As a consequence of this improved uptake, the treatment of the cells with DAB-Tf 
dendriplex resulted in an increase in gene expression on PC-3 and LNCaP cells, the 
improvement on DU145 being not significantly different from the gene expression 
level obtained with unconjugated DAB dendriplex. Our results were in agreement 
with the similarly improved gene expression observed by Yu et al. [24] when using 
immunolipoplexes targeting Tf receptors on prostate cancer cells.  
The use of DAB-Tf as a delivery system for TNF±, TRAIL and IL-12 expression 
plasmids significantly enhanced the in vitro therapeutic efficacy of the plasmids on 
the three prostate cancer cell lines studied, with improvements of up to 100-fold in 
LNCaP cells compared to the unconjugated dendriplex. The most efficacious 
treatment observed in this study was DAB-Tf dendriplex expressing TNF± on PC-3 
cells, which resulted in an IC50 of 0.27 r 0.04 µg/mL. Our results were in accordance 
with previously published works. Kaliberov and colleagues [25] have demonstrated 
that an adenoviral vector encoding the TRAIL gene under the control of the vascular 
endothelial growth factor receptor FLT1 promoter significantly increased DU145 cell 
death in comparison with the PC-3 cell line, following a similar trend to that observed 
in our results. In another study [26], adenoviral-mediated TRAIL treatment led to a 
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significant increase in cytotoxicity on PC-3 cells, with 85.5% of cells dead. However, 
the lack of IC50 values for these cell lines prevents comparison of the anti-proliferative 
effects of the viral and non-viral strategies. Furthermore, we could not find any 
studies describing the anti-proliferative effect of TNF±- and IL-12-mediated gene 
therapy on PC-3, DU145 and LNCaP prostate cancers to allow a comparison with 
our results. 
In our experiments, the IC50 obtained following administration of DAB-Tf dendriplex 
expressing TNF± was higher than those of TRAIL and Il-12 in DU145 cells, despite 
being the lowest in PC-3 and LNCaP cells. This may be explained by the sensitivity 
of these cell lines to the Fas ligand. TNF± is well known for its ability to induce 
apoptosis in a wide variety of cells. However, Rokhlin and colleagues [27] previously 
reported that Fas-sensitive PC-3 cell line was more sensitive to TNF± mediated 
apoptosis and growth inhibition than Fas-resistant DU145 and LNCaP cell lines. 
These results, in line with our observations, suggested that TNF± mediated apoptosis 
might be determined by factors that are common in both Fas and TNF± pathways.  
In vivo, we demonstrated that the intravenous administration of DAB-Tf dendriplex 
encoding TNF± resulted in tumor eradication of 60% of PC-3 and 50% of DU145 
tumors. In addition, treatment with DAB-Tf dendriplex encoding TRAIL also led to 
tumor eradication of 10% of PC-3 tumors. To our knowledge, it is the first time that 
the intravenous administration of tumor-targeted dendriplexes encoding TNF±, TRAIL 
and IL-12 on mice bearing prostate tumors, inhibited tumor growth and even led to a 
complete tumor suppression in some cases. Other researchers have previously 
demonstrated the ability of TNF±, TRAIL and IL-12-encoding DNA to induce a 
therapeutic effect on prostate tumors, but following intratumoral injection rather than 
intravenous administration, while using a viral delivery system rather than a non-viral 
 17 
one, and often in conjunction with other therapeutic modalities, such as radiotherapy 
[28], co-administration with oncolytic herpes simplex viruses [29], with adenoviral 
vector-mediated Herpes Simplex Virus / thymidine kinase and ganciclovir [30], or in 
addition with the drug mifepristone [31]. For example, the intratumoral administration 
of an adenoviral vector encoding the TRAIL gene under the control of FLT1 
promoter, in combination with radiation treatment, was shown to produce significant 
slowdown of the growth of DU145 tumor xenografts in athymic nude mice [25]. In 
another work, the intratumoral administration of a recombinant adenovirus 
expressing IL-12 was shown to significantly slowdown the growth of RM-9 prostate 
tumors [32].  Similar results were obtained by Saika and colleagues [33] following the 
intratumor administration of an adenovirus-mediated IL-12 on a 178-2 BMA prostate 
cancer model. The effects observed in these studies were generally a slowdown of 
tumor growth, rather than the tumor regression or suppression observed in some 
instances in our experiments.  
In the DU145 xenograft model, the therapeutic effect of DAB-Tf dendriplex encoding 
TNF± was more pronounced than that obtained with TRAIL and IL-12, contrarily to 
what was observed in our anti-proliferative assay in vitro.  This could be explained by 
the fact that TNF± exerts its potent cytotoxic effects on tumors in vivo via the death 
receptor-dependent apoptotic pathway, like TRAIL, but also via its anti-angiogenic 
effects, believed to be critical for its anti-cancer activity [34, 35]. It actually highlights 
the limitation of in vitro experiments for predicting the anti-cancer outcome of novel 
therapeutic systems in vivo. 
In this study, we have chosen to use, among other therapeutic agents, a plasmid 
DNA encoding IL-12. The biological effects of Il-12 encompass stimulation of 
unspecific immunity, such as via activation of NK cells, and stimulation of specific 
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immunity as mediated by cytotoxic T lymphocytes. In our experiments, we had to use 
immunodeficient BALB/c mice unable to produce T cells in order for them to grow 
subcutaneous tumors of human origin. We therefore hypothesize that the therapeutic 
effect observed could be further improved by using a fully immunocompetent mouse 
bearing a murine prostate tumor model [36].   
Our previous work, carried out with a therapeutic DNA encoding TNF± on A431 
epidermoid carcinoma tumors, demonstrated the tumor targeting capability of Tf-
bearing DAB dendrimer and led to a more pronounced therapeutic effect than that 
observed when using prostate tumor models [4]. These results highlight the 
difficulties encountered for the treatment of prostate tumors, independently of the 
therapeutic strategy chosen, and explain why so many studies use combinatorial 
modalities to improve the overall therapeutic effect. In this study, we wanted to 
evaluate the therapeutic efficacy of Tf-bearing DAB dendriplexes encoding TNF±, 
TRAIL and IL-12 on prostate tumor models following intravenous administration. 
Tumor-targeted TNF± gene therapy was more efficacious than TRAIL and IL-12, 
leading to tumor regression and even some tumor disappearance. Still, TRAIL and Il-
12-mediated gene therapy actually improved the therapeutic efficacy on prostate 
tumor models, compared to the slowdown of tumor growth generally observed 
following intratumoral administration of adenovirus-based gene medicines, and this 
without any combinatorial treatment. In addition, these tumor-targeted systems are 
intravenously delivered, thereby allowing them to reach metastases as well as 
primary tumors, which is particularly important for the treatment of prostate tumors.  
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CONCLUSIONS 
In this study, we have demonstrated for the first time that a tumor-targeting, 
dendrimer-based gene delivery system complexed to a plasmid DNA encoding TNF± 
and TRAIL can lead to eradication of some prostate tumors after intravenous 
administration. 
In vitro, DAB-Tf complexed to TNF±, TRAIL and IL-12 expression plasmids 
significantly enhanced the anti-proliferative efficacy on PC-3, DU145 and LNCaP 
prostate cancer cells when compared to the unconjugated dendriplex, by up to 100-
fold in LNCaP cells. 
In vivo, the intravenous administration of DAB-Tf dendriplex encoding TNF± resulted 
in tumor suppression for 60% of PC-3 and 50% of DU145 tumors. Treatment with of 
DAB-Tf dendriplex encoding TRAIL led to tumor suppression of 10% of PC-3 tumors.  
IL-12 mediated gene therapy resulted in tumor regression of 20% of both types of 
prostate tumors. By contrast, all the tumors treated with DAB-Tf, naked DNA or left 
untreated were progressive for both tumor types. The animals did not show any signs 
of toxicity.  
Transferrin-bearing DAB dendriplexes encoding TNF±, TRAIL and IL-12 therefore 
hold great potential as a novel approach for the gene therapy of prostate cancer and 
should be further investigated to optimize their therapeutic potential. 
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FUTURE PERSPECTIVE  
While gene therapy has been widely studied in laboratory settings for its therapeutic 
potential against cancer, little has been done regarding its intravenous, targeted 
administration to prostate tumors. This is a particularly important issue in the case of 
this cancer, as there is still no efficacious treatment modality for patients suffering 
from a recurrent disease or metastasis. In this study, we demonstrated for the first 
time that the intravenous administration of Tf-bearing DAB dendriplex encoding TNF± 
resulted in tumor suppression for 60% of PC-3 and 50% of DU145 tumors when 
using a TNF± encoding plasmid, and for 10% of PC-3 tumors when using a TRAIL 
encoding plasmid. We therefore hope that this breakthrough will lead to the 
development of tumor-targeted gene therapy for the treatment of prostate cancer.  
In addition, transferrin-bearing DAB dendriplexes encoding TNF±, TRAIL and IL-12 
should be further studied to optimize their therapeutic potential against cancer.  
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EXECUTIVE SUMMARY  
Introduction:  
x Gene therapy would be an attractive anti-cancer treatment strategy against 
advanced prostate cancer 
x Its use is limited by its failure to reach tumors in a specific way after 
intravenous administration 
 
In vitro therapeutic efficacy: 
x In vitro, transferrin-bearing dendriplex encoding TNF±, TRAIL and IL-12 
improved the anti-proliferative efficacy of the therapeutic DNA on PC-3, 
DU145 and LNCaP prostate cancer cells 
 
In vivo tumoricidal activity: 
x In vivo, the intravenous administration of DAB-Tf dendriplex encoding TNF± 
resulted in tumor disappearance for 60% of PC-3 and 50% of DU145 tumors. 
Treatment with of DAB-Tf dendriplex encoding TRAIL led to tumor 
disappearance for 10% of PC-3 tumors. Consequently, the survival of the 
treated mice was increased by 22 days compared to untreated tumors, for 
both cell lines.  
 
Conclusion: 
x Transferrin-bearing DAB dendriplexes encoding TNF±, TRAIL and IL-12 
therefore hold great potential as a novel approach for the gene therapy of 
prostate cancer and should be further investigated to optimize their 
therapeutic potential. 
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REFERENCE ANNOTATIONS  
Publications of special note have been highlighted as: 
* of interest 
** of considerable interest 
 
**  4 Koppu S, Oh YJ, Edrada-Ebel R, et al.: Tumor regression after systemic 
administration of a novel tumor-targeted gene delivery system carrying a therapeutic 
plasmid DNA. J. Control. Release 143, 215-221 (2010). 
Demonstrates for the first time that the intravenous administration of transferrin-
bearing DAB dendriplex encoding TNF± leads to tumor suppression of 90% of A431 
human epidermoid carcinoma tumors in mice 
 
** 25 Kaliberov SA, Kaliberova LN, Stockard CR, Grizzle WE, Buchsbaum DJ: 
Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate 
cancer. Mol. Ther. 10, 1059-1070 (2004). 
Demonstrates that the intratumoral administration of an adenoviral vector encoding 
the TRAIL gene under the control of FLT1 promoter, in combination with radiation 
treatment, produces significant slowdown of the growth of DU145 tumor xenografts in 
athymic nude mice 
 
** 32 Nasu Y, Bangma CH, Hull GW, et al.: Adenovirus-mediated interleukin-12 
gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-
established lung metastases in an orthotopic model. Gene Ther. 6, 338-349 (1999). 
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Demonstrates that the intratumoral administration of a recombinant adenovirus 
expressing IL-12 leads to a significantly slowdown of the growth of RM-9 prostate 
tumors 
 
** 33 Saika T, Kusaka N, Mouraviev V, et al.: Therapeutic effects of adoptive 
splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer 
model. Cancer Gene Ther. 13, 91-98 (2006). 
Demonstrates that the intratumoral administration of an adenovirus-mediated IL-12 
leads to a significant slowdown of the growth of a 178-2 BMA prostate cancer model. 
 
* 29 Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL: Enhanced 
therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex 
virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 13, 253-265 
(2006). 
Demonstrates that the expression of IL-12 further enhances the efficacy of the 
oncolytic herpes simplex viruses NV1023 in two murine prostate cancer models. 
 
* 30 Nasu Y, Bangma CH, Hull GW, et al.:  Combination gene therapy with 
adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for 
prostate cancer. Prostate Cancer Prostatic Dis. 4, 44-55 (2001). 
Describes the therapeutic effect of combination gene therapy with adenoviral vector-
mediated Herpes Simplex Virus / thymidine kinase and ganciclovir on prostate 
cancers. 
 
 29 
* 31 Gabaglia CR, DeLaney A, Gee J, et al.: Treatment combining RU486 and 
AdIL-12 vector attenuates the growth of experimentally formed prostate tumors and 
induces changes in the sentinel lymph nodes of mice. J. Transl. Med. 8, 1-10 (2010). 
Demonstrates that combinatorial approaches using an intratumorally administered 
recombinant adenovirus expressing IL-12 in conjunction with the drug mifepristone 
(RY486) improve the therapeutic efficacy in comparison to controls. 
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FIGURE LEGENDS 
Table 1. Anti-proliferative efficacy of TNF±-, TRAIL- and IL-12-encoding DNA 
complexed with DAB-Tf and DAB in PC-3, DU-145 and LNCaP prostate cancer cells, 
expressed as IC50 values (n=15) 
 
Figure 1. A) Confocal microscopy imaging of the cellular uptake of Cy3- labeled DNA 
(2.5 µg / well) either complexed with DAB-Tf, DAB or in solution, after incubation for 
72 hours with PC-3 (top) , DU145 (medium) and LNCaP cells (bottom) (Blue: nuclei 
stained with DAPI (excitation: 405 nm laser line, bandwidth: 415-491nm), green: Cy3-
labeled DNA (excitation: 543 nm laser line. bandwidth: 550-620 nm) (Bar: 10 µm).  
B) Quantification of Cy3-related fluorescence intensity per cell (in arbitrary units a.u.) 
in the confocal microscopy pictures obtained as described above (n=1). 
 
Figure 2. Transfection efficacy of DAB-Tf (“cplx DT”) and DAB dendriplexes (“cplx 
D”) in PC-3 (A), DU145 (B) and LNCaP cells (C). DAB-Tf and DAB dendriplexes were 
dosed at their optimal dendrimer: DNA ratio of 10:1 and 5:1 respectively. (Controls: 
DAB-Tf (“DT only”), DAB (“D only”) and naked DNA). Results are expressed as the 
mean ± SEM of three replicates (n=15). * : P <0.05 vs the highest transfection ratio. 
 
Figure 3. A) Tumor growth studies in a PC-3 xenograft model after intravenous 
administration of transferrin- bearing DAB dendriplex carrying plasmid DNA encoding 
TNF± (green), TRAIL (red), IL-12 (blue) (50 µg DNA / injection),  uncomplexed DAB-
Tf (brown), naked DNA encoding TNF± (pale green), naked DNA encoding TRAIL 
(orange), naked DNA encoding IL-12 (pale blue), untreated tumors (back) (n=10).  
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B) Variations of the animal body weight throughout the treatment (Color coding as in 
A). 
C) Overall tumor response to treatments at the end of the study, classified in 
accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) [37]. 
D) Time to disease progression.  The Y axis gives the proportion of surviving animals 
over time. Animals were removed from the study once their tumor reached 12 mm 
diameter (Color coding as in A). 
 
Figure 4. A) Tumor growth studies in a DU145 xenograft model after intravenous 
administration of transferrin- bearing DAB dendriplex carrying plasmid DNA encoding 
TNF± (green), TRAIL (red), IL-12 (blue) (50 µg DNA / injection),  uncomplexed DAB-
Tf (brown), naked DNA encoding TNF± (pale green), naked DNA encoding TRAIL 
(orange), naked DNA encoding IL-12 (pale blue), untreated tumors (back) (n=10).  
B) Variations of the animal body weight throughout the treatment (Color coding as in 
A). 
C) Overall tumor response to treatments at the end of the study. 
D) Time to disease progression.  The Y axis gives the proportion of surviving animals 
over time. Animals were removed from the study once their tumor reached 12 mm 
diameter (Color coding as in A). 
 
Figure 5. Bioluminescence imaging of the tumoricidal activity of transferrin- bearing 
DAB dendriplex carrying plasmid DNA encoding TNF± (•cplx DT-TNF”), TRAIL (“cplx 
DT-TRAIL”), IL-12 (“cplx DT-IL12”) in a PC-3M-luc-C6 tumor model. Controls: naked 
DNA and untreated tumors. The scale indicates surface radiance 
(photons/s/cm2/steradian).  
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